Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of afatinib in metastatic colorectal cancer without prior anti-EGFR therapy
2009-011996-59Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib in colorectal cancer (CRC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Overall response rate, Objective response rate in KRAS wild-type subgroup and 1 more. Started Apr 2010; status: completed.
02
Drugs
afatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-011996-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011996-59.